Vestibular Migraine: Acute and Preventive Treatment Strategies
Flunarizine 5–10 mg once daily should be considered the first-line preventive medication for vestibular migraine based on two randomized clinical trials demonstrating efficacy, followed by beta-blockers (propranolol 80–240 mg/day), topiramate (50–100 mg/day), or candesartan as alternative first-line options. 1, 2
Diagnostic Confirmation Before Treatment
- Vestibular migraine requires ≥5 episodes of vestibular symptoms lasting 5 minutes to 72 hours, with at least half accompanied by migrainous features (headache, photophobia, phonophobia, or visual aura). 1
- Rule out central causes (stroke, multiple sclerosis) by screening for red flags: downbeating nystagmus on Dix-Hallpike, direction-changing nystagmus without head position changes, gaze-holding nystagmus, dysarthria, dysmetria, dysphagia, sensory/motor deficits, or Horner's syndrome. 1
- Distinguish from Ménière's disease by documenting that hearing loss is mild, bilateral, and stable (rather than fluctuating low-to-mid-frequency sensorineural loss on audiometry), and that vertigo attacks last 5 minutes to 72 hours (rather than 20 minutes to 12 hours). 1
- Note that 35% of Ménière's patients also meet vestibular migraine criteria; noninvasive therapeutic trials should precede surgical or ablative interventions. 1
Acute (Abortive) Treatment During Attacks
First-Line Acute Options
- Triptans (sumatriptan 50–100 mg oral, rizatriptan 10 mg, or intranasal sumatriptan 5–20 mg) are the primary acute treatment for concurrent headache during vestibular migraine attacks, though evidence is conflicting. 1, 2, 3
- Antiemetic medications (diphenhydramine, meclizine, metoclopramide 10 mg) can ameliorate nausea and vertigo during acute attacks. 1, 3
Vestibular Suppressants (Short-Term Only)
- Centrally acting anticholinergics (scopolamine) or benzodiazepines may suppress acute vertigo but carry significant side effects and dependency risk; they are not recommended for long-term use. 1
Neuromodulatory Devices
- Neurostimulating devices can be considered for acute treatment of vestibular migraine attacks. 2
Critical Frequency Limitation
- Limit all acute medications to ≤2 days per week (≤10 days per month) to prevent medication-overuse headache, which can increase attack frequency and lead to daily symptoms. 4, 1
Preventive (Prophylactic) Treatment
Indications for Initiating Prevention
- ≥2 vestibular migraine attacks per month causing disability lasting ≥3 days. 5, 1
- Acute medication use >2 days per week despite optimized acute treatment. 5, 1
- Contraindication to or failure of acute therapies. 5
- Patient preference for a preventive approach. 5
First-Line Preventive Medications
Flunarizine (Preferred First-Line Based on RCT Evidence)
- Flunarizine 5–10 mg once daily (taken at night) is the only preventive medication with two randomized clinical trials specifically in vestibular migraine and should be considered the preferred first-line option. 1, 2, 6
- Contraindications: active Parkinsonism, history of extrapyramidal disorders, current depression. 5
- Common adverse effects: sedation, weight gain, abdominal pain; serious effects (especially in elderly): depression, extrapyramidal symptoms. 5
- Screen for depression and Parkinson's disease before initiating; avoid in elderly patients. 5
Beta-Blockers (Alternative First-Line)
- Propranolol 80–240 mg/day (doses <160 mg/day are generally sub-therapeutic) has the strongest evidence among traditional preventives and is FDA-approved for migraine prophylaxis. 5, 1, 7
- Alternative beta-blockers: metoprolol, atenolol, bisoprolol, nadolol, timolol 20–30 mg/day. 5, 1
- Particularly useful for patients with comorbid hypertension. 5, 1
- Contraindications: asthma, heart block, severe peripheral vascular disease. 5
Topiramate (Alternative First-Line)
- Topiramate 50–100 mg/day (typically 50 mg twice daily) is especially beneficial in obese patients due to associated weight loss. 5, 1, 8
- Common adverse effects: cognitive inefficiency, paresthesia, fatigue, weight loss. 1
- Strictly contraindicated in women of childbearing potential without effective contraception due to teratogenic risk. 5
Candesartan (Alternative First-Line)
- Candesartan (angiotensin-receptor blocker) is particularly useful for patients with comorbid hypertension. 5, 1
Second-Line Preventive Medications
Tricyclic Antidepressants
- Amitriptyline 30–150 mg/day or nortriptyline are particularly useful for patients with coexisting anxiety, depression, or sleep disturbances. 1, 3, 8
- Amitriptyline lacks robust RCT evidence specifically for chronic migraine but is effective for episodic migraine and mixed headache patterns. 5
Valproic Acid/Divalproex Sodium
- Valproic acid 600–1,500 mg/day or divalproex sodium 500–1,500 mg/day are effective second-line options. 1, 3, 8
- Absolutely contraindicated in women of childbearing potential due to teratogenic effects. 5, 1
- Common adverse effects: weight gain, hair loss, tremor. 5
Venlafaxine
- Venlafaxine is a second-line option for vestibular migraine prevention. 8
Third-Line Preventive Medications (Refractory Cases)
CGRP Monoclonal Antibodies
- Erenumab 70 or 140 mg subcutaneous once monthly, fremanezumab 225 mg subcutaneous once monthly or 675 mg quarterly, galcanezumab, or eptinezumab 100 or 300 mg intravenous quarterly should be considered after failure of first- and second-line agents. 1, 7
- Assess efficacy after 3–6 months of therapy. 5, 1
- Galcanezumab offers the best balance of efficacy, tolerability, and evidence quality among CGRP antagonists, with zero discontinuations in trials. 7
OnabotulinumtoxinA
- OnabotulinumtoxinA 155–195 units to 31–39 sites every 12 weeks is the only FDA-approved therapy for chronic migraine with vestibular symptoms. 1
- Assess efficacy after 6–9 months. 5, 1
Non-Pharmacological Preventive Approaches
Lifestyle Modifications (Essential First-Line Intervention)
- Limit salt/sodium intake, avoid excessive caffeine, alcohol, and nicotine. 1
- Eat well-balanced meals, maintain adequate hydration. 1
- Manage stress through relaxation techniques, stress management, and biofeedback. 1, 3
- Regular exercise has been shown to be as effective as pharmacological approaches when combined with other interventions. 1, 3
- Establish regular sleep patterns; screen and treat obstructive sleep apnea. 1
- Identify and manage allergies. 1
Biobehavioral Therapy
- Relaxation techniques, stress management, and biofeedback can be as effective as pharmacological approaches and should be combined with medication. 1, 3
Vestibular Rehabilitation
- Vestibular rehabilitation may be useful for chronic imbalance between attacks and appears to be a sound prophylactic treatment option. 1, 2
Neuromodulatory Devices
- Neuromodulatory devices can be considered as adjuncts or stand-alone treatment when medication is contraindicated. 1
Acupuncture
- Acupuncture has some supporting evidence for vestibular migraine prevention, though not superior to sham acupuncture. 1
Treatment Implementation Algorithm
Step 1: Lifestyle Modifications + Acute Treatment Plan
- Implement all lifestyle modifications (sleep hygiene, stress management, dietary triggers, regular exercise). 1
- Provide acute treatment (triptans + antiemetics) with strict frequency limits (≤2 days/week). 1
Step 2: Initiate First-Line Preventive Medication
- If flunarizine is available and no contraindications exist (no Parkinsonism, no depression, not elderly): start flunarizine 5–10 mg once daily. 1, 2
- If flunarizine is unavailable or contraindicated:
Step 3: Titrate and Assess
- Start at low dose and titrate slowly over several weeks to target therapeutic dose. 5
- Assess efficacy after 2–3 months at therapeutic dose using headache diary and validated disability tools (Migraine Disability Assessment Score, HIT-6). 5, 1
Step 4: Switch or Add Second-Line Agent
- If first-line agent fails after adequate trial (2–3 months at target dose), switch to an alternative first-line agent (failure of one class does not predict failure of others). 5
- If two first-line agents fail, escalate to second-line agents (amitriptyline, venlafaxine, or valproate if male). 1, 8
Step 5: Escalate to Third-Line Therapy
- If two oral preventives fail, escalate to CGRP monoclonal antibodies (galcanezumab preferred for best tolerability) or onabotulinumtoxinA for chronic migraine with vestibular symptoms. 1, 7
- Assess efficacy after 3–6 months for CGRP antibodies or 6–9 months for onabotulinumtoxinA. 5, 1
Step 6: Reassess and Consider Pausing
- After 6–12 months of successful control, consider pausing preventive therapy to determine if it can be discontinued. 5, 1
Critical Pitfalls to Avoid
- Do not use vestibular suppressants long-term; they are for acute attacks only and carry dependency risk. 1
- Do not prescribe opioids or barbiturates for vestibular migraine due to questionable efficacy, dependency risk, and medication-overuse headache. 1
- Do not abandon treatment prematurely; oral preventives require 2–3 months at target dose before efficacy can be judged. 5, 1
- Do not maintain sub-therapeutic doses (e.g., propranolol <160 mg/day) indefinitely; optimize dose before declaring treatment failure. 5
- Do not fail to recognize and manage comorbidities (anxiety, depression, sleep disturbances, obesity, medication overuse). 1
- Do not prescribe valproate to women of childbearing potential without strict contraception counseling due to teratogenic risk. 5, 1
- Do not use positive pressure therapy (e.g., CPAP) for vestibular migraine; it does not improve vestibular symptoms and may worsen the condition. 1
Comorbidity Management
- Identify and manage modifiable risk factors: obesity, medication overuse, excessive caffeine use, obstructive sleep apnea, psychiatric comorbidities (anxiety, depression), and stress. 1
- Screen for and treat anxiety and depression, which are frequently found in vestibular migraine and can impair treatment response. 9
Patient Education
- Educate patients on the biological basis of vestibular migraine, emphasizing that it requires multimodal therapy (lifestyle + medication + behavioral interventions). 1
- Set realistic expectations that efficacy is rarely observed immediately and may take several weeks to months. 1
- Emphasize treatment adherence; simplified dosing schedules improve adherence. 1
- Explain that failure of one preventive treatment does not predict failure of other drug classes. 1
- Encourage patients to maintain a headache diary to facilitate monitoring of migraine attacks and vestibular episodes. 1